Predicting Peptide Solubility: Charge, Hydrophobicity and Solvent Choice

In plain English

Some peptides dissolve in water in seconds. Others form a cloudy suspension and refuse to dissolve. The difference comes mostly from the sequence (the order of amino acids, the building blocks of peptides).

Two things matter most. The first is electric charge. Charged molecules push each other apart and attract water, which helps them dissolve. Each peptide has a pH (a measure of acidity) at which its charges cancel out. This is the isoelectric point, and solubility is usually lowest there ^{[1, 2]}. The second is how “water-hating” (hydrophobic) the amino acids are. Oily side chains tend to stick together instead of mixing with water ^{[3, 4]}.

Scientists can estimate both from the sequence before opening a vial. Computer tools can also predict solubility, but their predictions are still checked by experiment ^{[5, 6]}.

The short version

• Charged peptides usually dissolve more easily.
• Solubility is lowest near the isoelectric point.
• Many hydrophobic residues means a harder-to-dissolve peptide.
• Test a small portion first.

Why solubility matters at the bench

A peptide that has not fully dissolved gives a lower true concentration than the calculation suggests, and particles or aggregates can interfere with assays. Physical instability of peptides includes both amorphous aggregates and highly ordered fibrils. A review of peptide aggregation lists sequence, concentration, pH, net charge, excipients, surfaces and temperature among the factors that control it ^[4]. Getting the solvent right at the start avoids many of these problems.

Step 1: estimate net charge at pH 7

Count the ionisable groups in the sequence:

These are approximations. Actual pKa values shift with neighbouring residues, and web tools that predict pI and pKa from sequence are more accurate than simple counting ^[2].

Step 2: estimate hydrophobicity

The Kyte–Doolittle hydropathy scale assigns each amino acid a score, from strongly hydrophobic (isoleucine +4.5, valine +4.2, leucine +3.8, phenylalanine +2.8) to strongly hydrophilic (arginine −4.5, lysine −3.9, aspartic acid and glutamic acid −3.5) ^[3]. The average score across a sequence (often called GRAVY, grand average of hydropathy) gives a quick overall picture:

• Clearly negative average: hydrophilic; usually water-soluble if charged.
• Near zero: mixed; charge often decides.
• Clearly positive average: hydrophobic; likely to need an organic co-solvent.

Not all hydrophilic residues contribute equally. In a systematic study of a model protein, aspartic acid, glutamic acid and serine contributed more favourably to solubility than other hydrophilic amino acids, especially at high net charge ^[7].

Worked examples

Example 1: bradykinin (RPPGFSPFR)

Bradykinin is a nine-residue peptide with molecular formula C₅₀H₇₃N₁₅O₁₁ ^[8].

• Charge at pH 7: N-terminus +1, R +1, R +1, C-terminus −1 = +2
• Kyte–Doolittle average: (−4.5 −1.6 −1.6 −0.4 +2.8 −0.8 −1.6 +2.8 −4.5) ÷ 9 = −1.04
• Prediction: basic and hydrophilic. Water is the first choice; dilute acetic acid is the fallback.

Example 2: an illustrative acidic peptide (EDGSEAK)

• Charge at pH 7: N-terminus +1, E −1, D −1, E −1, K +1, C-terminus −1 = −2
• Kyte–Doolittle average: (−3.5 −3.5 −0.4 −0.8 −3.5 +1.8 −3.9) ÷ 7 = −1.97
• Prediction: acidic and hydrophilic. Water or a neutral buffer first; a slightly basic aqueous solution if needed.

Example 3: an illustrative hydrophobic peptide (Ac-LVIAFGL-NH₂)

• Charge at pH 7: both termini capped, no charged side chains = 0
• Kyte–Doolittle average: (3.8 + 4.2 + 4.5 + 1.8 + 2.8 − 0.4 + 3.8) ÷ 7 = +2.93
• Prediction: neutral and strongly hydrophobic. Likely to need a small volume of DMSO or another organic co-solvent, followed by slow dilution.

Examples 2 and 3 are hypothetical sequences chosen to show the arithmetic.

Step 3: choose the solvent

DMSO and sulfur-containing peptides. DMSO is an oxidant. In one study, linear peptides with free cysteine thiols formed disulfide dimers and highly oxidised by-products when exposed to DMSO, depending on peptide structure ^[9]. For cysteine- or methionine-containing sequences, keep DMSO exposure short or choose a different co-solvent.

pH moves solubility. Experiments on a disordered protein showed that its aggregation could be tuned by pH and depended on net charge per residue ^[1]. Moving the pH a unit or two away from the pI is often enough to change a cloudy suspension into a clear solution.

Practical tips when a peptide won’t dissolve

1. Test a small weighed portion before committing the whole vial.
2. Add the organic solvent first for hydrophobic peptides, then add water or buffer. Adding DMSO to an already cloudy aqueous suspension works less well.
3. Use brief sonication in a water bath, watching for heating.
4. Lower the concentration. Solubility limits are concentration-dependent, and aggregation increases with concentration ^[4].
5. Check the counter-ion. Trifluoroacetate and acetate salts can behave differently. See Peptide Counter-Ions.
6. Watch for surface loss. At low concentrations, cationic peptides can adsorb to glass and plastic; in one study, 90% or more was lost from solution ^[10]. Low-binding tubes reduce this.
7. Inspect the result. A true solution is clear. Cloudiness, a gel or visible particles means the peptide is not fully dissolved or has aggregated.

For the full bench workflow, including concentration maths and aseptic technique, see Units and Calculations.

Computational prediction

Sequence-based tools go beyond charge counting. The CamSol method predicts intrinsic solubility from sequence and was used to design more soluble protein variants ^[5]. An extension, CamSol-PTM, predicts the solubility of peptides containing modified amino acids; its predictions agreed with experimental values across 37 tested peptide variants ^[6]. Such tools are screening aids. The final answer always comes from dissolving the actual material.

What this means in Australia

• Solubility is chemistry, not legal status. Whether a peptide dissolves in water or DMSO has no bearing on how it is regulated. Unapproved peptide products are not entered on the Australian Register of Therapeutic Goods (ARTG) and have not been assessed by the TGA ^[11].
• Scheduling depends on the substance. Several peptides are named in the current Poisons Standard (October 2026), some as Schedule 4 (prescription-only) and Appendix D, clause 5 (possession without authority is illegal) ^[12].
• Labels don’t change status. The TGA has stated that a “research use only” disclaimer does not make supply lawful, change regulatory status, permit importation, or remove advertising or supply obligations ^[11].
• Solvents are hazardous chemicals. DMSO, acetonitrile and acetic acid are workplace chemicals covered by Australian work health and safety duties. See Safety Data Sheets and Lab Safety.

This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.

Frequently asked questions

How can I tell if a peptide will dissolve in water?

Count its charges at pH 7 and average its hydropathy scores. Peptides with a clear net charge and a negative hydropathy average usually dissolve in water ^{[1, 3]}.

What is the isoelectric point of a peptide?

It is the pH at which the peptide’s positive and negative charges balance, so net charge is zero. Solubility is usually lowest near this pH ^[2].

When should DMSO be used to dissolve a peptide?

DMSO is used for neutral, strongly hydrophobic peptides, in the smallest volume that works, before slow dilution. It can oxidise free cysteine thiols ^[9].

Why did my peptide precipitate when buffer was added?

Diluting an organic stock into water lowers the co-solvent fraction, and the buffer pH may sit near the peptide’s pI. Adding buffer more slowly, or lowering the final concentration, often helps ^[4].

Are solubility prediction tools reliable?

They are good screening tools, and some have been validated against measured solubility, but they don’t replace a small test dissolution ^{[5, 6]}.

References

1. Tedeschi G, Mangiagalli M, Chmielewska S, Lotti M, Natalello A, Brocca S. Aggregation properties of a disordered protein are tunable by pH and depend on its net charge per residue. Biochim Biophys Acta Gen Subj. 2017;1861(11 Pt A):2543–2550. doi:10.1016/j.bbagen.2017.09.002. PMID: 28890401
2. Kozlowski LP. IPC 2.0: prediction of isoelectric point and pKa dissociation constants. Nucleic Acids Res. 2021;49(W1):W285–W292. doi:10.1093/nar/gkab295. PMID: 33905510
3. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157(1):105–132. doi:10.1016/0022-2836(82)90515-0. PMID: 7108955
4. Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. doi:10.1098/rsfs.2017.0030. PMID: 29147559
5. Sormanni P, Aprile FA, Vendruscolo M. The CamSol method of rational design of protein mutants with enhanced solubility. J Mol Biol. 2015;427(2):478–490. doi:10.1016/j.jmb.2014.09.026. PMID: 25451785
6. Oeller M, Kang RJD, Bolt HL, et al. Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids. Nat Commun. 2023;14(1):7475. doi:10.1038/s41467-023-42940-w. PMID: 37978172
7. Trevino SR, Scholtz JM, Pace CN. Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa. J Mol Biol. 2007;366(2):449–460. doi:10.1016/j.jmb.2006.10.026. PMID: 17174328
8. National Center for Biotechnology Information. PubChem Compound Summary for CID 439201, Bradykinin. pubchem.ncbi.nlm.nih.gov/compound/439201
9. Liu S, Zhou L, Chen L, et al. Effect of structural parameters of peptides on dimer formation and highly oxidized side products in the oxidation of thiols of linear analogues of human beta-defensin 3 by DMSO. J Pept Sci. 2009;15(2):95–106. doi:10.1002/psc.1100. PMID: 19108000
10. Kristensen K, Henriksen JR, Andresen TL. Adsorption of cationic peptides to solid surfaces of glass and plastic. PLoS One. 2015;10(5):e0122419. doi:10.1371/journal.pone.0122419. PMID: 25932639
11. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 11 October 2026.
12. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation. legislation.gov.au. Accessed 11 October 2026.

Important information and disclaimer

General information only. This article is published for general educational and informational purposes. It summarises published scientific literature and public regulatory information as at the “last reviewed” date shown above. It is not medical, health, pharmaceutical, veterinary or legal advice, and it must not be relied on as a substitute for advice from a qualified professional about your circumstances.

Not for human or animal use. Nothing in this article recommends, endorses or describes the use of any substance in humans or animals. Findings from cell, animal or early human studies cannot be assumed to apply to people. The compounds discussed have not been evaluated by the Therapeutic Goods Administration (TGA) for safety, quality or efficacy unless the article expressly states otherwise. Any research materials offered by Iconic Peptides are supplied solely for in vitro and laboratory research.

No therapeutic claims. Iconic Peptides makes no claim that any product treats, cures, prevents, alleviates or diagnoses any disease, condition or symptom. References to published studies, clinical trials or medicines approved by regulators are factual descriptions of the scientific and regulatory record. They are not representations about any product we supply.

Regulatory status. Many peptides are scheduled substances under the Poisons Standard. Some are prescription-only (Schedule 4), and some may not be possessed without authority (Appendix D). The TGA has stated that a “research use only” label does not make supply lawful, change a product’s regulatory status, or remove advertising or supply obligations. State and territory laws may also apply. You are responsible for knowing and complying with all laws that apply to you. Regulatory information in this article may change after the review date.

Accuracy and third-party sources. We take care to cite and verify every source, but we do not warrant that this article is complete, current or error-free. Citing a study or organisation does not mean that its authors or that organisation endorse Iconic Peptides.

Limitation of liability. To the maximum extent permitted by law, Iconic Peptides, its owners, employees and contributors exclude all liability for any loss, damage, injury or expense, whether direct, indirect or consequential, arising from use of or reliance on this article or any misuse of any product. Nothing in this disclaimer excludes, restricts or modifies any right or remedy under the Australian Consumer Law that cannot lawfully be excluded.

Age restriction. This website is intended for adults aged 18 and over.